Compare $CBIO vs $RGNX | Chartloom

Compare

$CBIO vs $RGNX

Crescent Biopharma Inc · Regenxbio Inc

CBIO

Crescent Biopharma Inc

RGNX

Regenxbio Inc

Compare $CBIO vs $RGNX

Comparing Crescent Biopharma Inc and Regenxbio Inc

CBIOCrescent Biopharma Inc

RGNXRegenxbio Inc

CBIOCrescent Biopharma Inc

Market cap

$532M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

34.6%

52W performance

23.6%

FCF yield

-28.9%

RGNXRegenxbio Inc

Market cap

$511M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.95x

Rev growth (TTM)

12.0%

YTD performance

-40.5%

52W performance

-34.0%

FCF yield

-48.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CBIO

RGNX

Detailed metrics comparison

CBIO

Crescent Biopharma Inc

RGNX

Regenxbio Inc

Market Cap

CBIO$532M

RGNX$511M

Enterprise Value

CBIO$360M

RGNX$656M

Price

CBIO$14.91

RGNX$8.07

P/E Ratio

CBION/A

RGNXN/A

P/S Ratio

CBIO44.76x

RGNX2.93x

EV/Sales

CBIO30.32x

RGNX3.76x

EV/EBITDA

CBIO0.00x

RGNX5.30x

P/B Ratio

CBIO3.26x

RGNX6.83x

P/FCF Ratio

CBION/A

RGNXN/A

EV/FCF

CBIO-2.35x

RGNX-2.63x

PEG Ratio

CBION/A

RGNXN/A

Forward P/E (NTM)

CBION/A

RGNXN/A

Forward P/S (NTM)

CBION/A

RGNX5.95x

Revenue (TTM)

CBIO$12M

RGNX$174M

Revenue Growth (YoY)

CBION/A

RGNX12.0%

Forward Rev Growth

CBIO-15.7%

RGNX25.9%

Gross Margin (TTM)

CBIO0.0%

RGNX86.4%

Operating Margin (TTM)

CBIO0.0%

RGNX0.0%

EBITDA Margin (TTM)

CBIO-1355.3%

RGNX-85.3%

Net Margin (TTM)

CBIO-1406.4%

RGNX-112.6%

FCF Margin (TTM)

CBIO-1292.8%

RGNX-143.1%

Net Income (TTM)

CBIO$-167M

RGNX$-196M

FCF (TTM)

CBIO$-154M

RGNX$-250M

EPS (TTM)

CBIO-$5.47

RGNX-$3.71

ROE (TTM)

CBIO-10026.0%

RGNX-22007.0%

ROA (TTM)

CBIO-8791.0%

RGNX-4604.0%

ROIC (TTM)

CBIO-10026.0%

RGNX-7179.0%

Cash

CBIO$172M

RGNX$36M

Debt

CBIO$0

RGNX$182M

Net Cash/Debt

CBIO$172M

RGNX$-145M

Current Ratio (TTM)

CBIO9.66x

RGNX2.86x

Quick Ratio (TTM)

CBIO9.26x

RGNX2.71x

Debt/Equity (TTM)

CBIO0.00x

RGNX2.53x

Debt/Assets (TTM)

CBIO0.0%

RGNX0.0%

Interest Coverage (TTM)

CBION/A

RGNXN/A

Net Debt/EBITDA (TTM)

CBIO0.00x

RGNX0.00x

Beta

CBIO1.39

RGNX1.21

52W Performance

CBIO23.6%

RGNX-34.0%

YTD Performance

CBIO34.6%

RGNX-40.5%

% from 52W High

CBIO-45.6%

RGNX-50.2%

% from 52W Low

CBIO71.0%

RGNX47.9%

Asset Turnover (TTM)

CBIO0.05x

RGNX0.41x

FCF Yield (TTM)

CBIO-28.9%

RGNX-48.9%

Earnings Yield (TTM)

CBIO-31.4%

RGNX-38.5%

Dividend Yield (TTM)

CBION/A

RGNXN/A

Rule of 40

CBIO-1,292.8

RGNX-131.1

EV/GP/RG

CBION/A

RGNX0.15

Ticker research

View CBIO research View RGNX research

Metric	CBIO Crescent Biopharma Inc	RGNX Regenxbio Inc
Market & Valuation
Market Cap	$532M	$511M
Enterprise Value	$360M	$656M
Price	$14.91	$8.07
P/E Ratio	N/A	N/A
P/S Ratio	44.76x	2.93x
EV/Sales	30.32x	3.76x
EV/EBITDA	0.00x	5.30x
P/B Ratio	3.26x	6.83x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.35x	-2.63x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	5.95x
Revenue & Growth
Revenue (TTM)	$12M	$174M
Revenue Growth (YoY)	N/A	12.0%
Forward Rev Growth	-15.7%	25.9%
Profitability
Gross Margin (TTM)	0.0%	86.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1355.3%	-85.3%
Net Margin (TTM)	-1406.4%	-112.6%
FCF Margin (TTM)	-1292.8%	-143.1%
Net Income (TTM)	$-167M	$-196M
FCF (TTM)	$-154M	$-250M
EPS (TTM)	-$5.47	-$3.71
ROE (TTM)	-10026.0%	-22007.0%
ROA (TTM)	-8791.0%	-4604.0%
ROIC (TTM)	-10026.0%	-7179.0%
Financial Health
Cash	$172M	$36M
Debt	$0	$182M
Net Cash/Debt	$172M	$-145M
Current Ratio (TTM)	9.66x	2.86x
Quick Ratio (TTM)	9.26x	2.71x
Debt/Equity (TTM)	0.00x	2.53x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.39	1.21
52W Performance	23.6%	-34.0%
YTD Performance	34.6%	-40.5%
% from 52W High	-45.6%	-50.2%
% from 52W Low	71.0%	47.9%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.41x
FCF Yield (TTM)	-28.9%	-48.9%
Earnings Yield (TTM)	-31.4%	-38.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,292.8	-131.1
EV/GP/RG	N/A	0.15
Ticker research	View CBIO research	View RGNX research

Valuation

P/S Ratio

RGNX

2.93x

CBIO

44.76x

EV/FCF

RGNX

-2.63x

CBIO

-2.35x

Growth & revenue

Revenue Growth TTM

RGNX

12.0%

Forward Revenue Growth

RGNX

25.9%

CBIO

-15.7%

Profitability & performance

Gross Margin

RGNX

86.4%

CBIO

0.0%

ROE

CBIO

-10026.0%

RGNX

-22007.0%

FCF Yield %

CBIO

-28.9%

RGNX

-48.9%

52-Week Performance

CBIO

23.6%

RGNX

-34.0%

Detailed metrics comparison

CBIO

Crescent Biopharma Inc

RGNX

Regenxbio Inc

Market Cap

CBIO$532M

RGNX$511M

Enterprise Value

CBIO$360M

RGNX$656M

Price

CBIO$14.91

RGNX$8.07

P/E Ratio

CBION/A

RGNXN/A

P/S Ratio

CBIO44.76x

RGNX2.93x

EV/Sales

CBIO30.32x

RGNX3.76x

EV/EBITDA

CBIO0.00x

RGNX5.30x

P/B Ratio

CBIO3.26x

RGNX6.83x

P/FCF Ratio

CBION/A

RGNXN/A

EV/FCF

CBIO-2.35x

RGNX-2.63x

PEG Ratio

CBION/A

RGNXN/A

Forward P/E (NTM)

CBION/A

RGNXN/A

Forward P/S (NTM)

CBION/A

RGNX5.95x

Revenue (TTM)

CBIO$12M

RGNX$174M

Revenue Growth (YoY)

CBION/A

RGNX12.0%

Forward Rev Growth

CBIO-15.7%

RGNX25.9%

Gross Margin (TTM)

CBIO0.0%

RGNX86.4%

Operating Margin (TTM)

CBIO0.0%

RGNX0.0%

EBITDA Margin (TTM)

CBIO-1355.3%

RGNX-85.3%

Net Margin (TTM)

CBIO-1406.4%

RGNX-112.6%

FCF Margin (TTM)

CBIO-1292.8%

RGNX-143.1%

Net Income (TTM)

CBIO$-167M

RGNX$-196M

FCF (TTM)

CBIO$-154M

RGNX$-250M

EPS (TTM)

CBIO-$5.47

RGNX-$3.71

ROE (TTM)

CBIO-10026.0%

RGNX-22007.0%

ROA (TTM)

CBIO-8791.0%

RGNX-4604.0%

ROIC (TTM)

CBIO-10026.0%

RGNX-7179.0%

Cash

CBIO$172M

RGNX$36M

Debt

CBIO$0

RGNX$182M

Net Cash/Debt

CBIO$172M

RGNX$-145M

Current Ratio (TTM)

CBIO9.66x

RGNX2.86x

Quick Ratio (TTM)

CBIO9.26x

RGNX2.71x

Debt/Equity (TTM)

CBIO0.00x

RGNX2.53x

Debt/Assets (TTM)

CBIO0.0%

RGNX0.0%

Interest Coverage (TTM)

CBION/A

RGNXN/A

Net Debt/EBITDA (TTM)

CBIO0.00x

RGNX0.00x

Beta

CBIO1.39

RGNX1.21

52W Performance

CBIO23.6%

RGNX-34.0%

YTD Performance

CBIO34.6%

RGNX-40.5%

% from 52W High

CBIO-45.6%

RGNX-50.2%

% from 52W Low

CBIO71.0%

RGNX47.9%

Asset Turnover (TTM)

CBIO0.05x

RGNX0.41x

FCF Yield (TTM)

CBIO-28.9%

RGNX-48.9%

Earnings Yield (TTM)

CBIO-31.4%

RGNX-38.5%

Dividend Yield (TTM)

CBION/A

RGNXN/A

Rule of 40

CBIO-1,292.8

RGNX-131.1

EV/GP/RG

CBION/A

RGNX0.15

Ticker research

View CBIO research View RGNX research

Metric	CBIO Crescent Biopharma Inc	RGNX Regenxbio Inc
Market & Valuation
Market Cap	$532M	$511M
Enterprise Value	$360M	$656M
Price	$14.91	$8.07
P/E Ratio	N/A	N/A
P/S Ratio	44.76x	2.93x
EV/Sales	30.32x	3.76x
EV/EBITDA	0.00x	5.30x
P/B Ratio	3.26x	6.83x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.35x	-2.63x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	5.95x
Revenue & Growth
Revenue (TTM)	$12M	$174M
Revenue Growth (YoY)	N/A	12.0%
Forward Rev Growth	-15.7%	25.9%
Profitability
Gross Margin (TTM)	0.0%	86.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1355.3%	-85.3%
Net Margin (TTM)	-1406.4%	-112.6%
FCF Margin (TTM)	-1292.8%	-143.1%
Net Income (TTM)	$-167M	$-196M
FCF (TTM)	$-154M	$-250M
EPS (TTM)	-$5.47	-$3.71
ROE (TTM)	-10026.0%	-22007.0%
ROA (TTM)	-8791.0%	-4604.0%
ROIC (TTM)	-10026.0%	-7179.0%
Financial Health
Cash	$172M	$36M
Debt	$0	$182M
Net Cash/Debt	$172M	$-145M
Current Ratio (TTM)	9.66x	2.86x
Quick Ratio (TTM)	9.26x	2.71x
Debt/Equity (TTM)	0.00x	2.53x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.39	1.21
52W Performance	23.6%	-34.0%
YTD Performance	34.6%	-40.5%
% from 52W High	-45.6%	-50.2%
% from 52W Low	71.0%	47.9%
Efficiency & Yields
Asset Turnover (TTM)	0.05x	0.41x
FCF Yield (TTM)	-28.9%	-48.9%
Earnings Yield (TTM)	-31.4%	-38.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,292.8	-131.1
EV/GP/RG	N/A	0.15
Ticker research	View CBIO research	View RGNX research